May 14, 2024 – Page 10 – Goldea Capital

Janover Reports First Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Achieves 17% Sequential Increase in Revenue for Q1 2024 Compared to Q4 2023 18% of the Total Revenue Consisted of Recurring Revenue Quarterly Revenue Per Transaction Increased 10% BOCA RATON, Fla., May 14, 2024 (GLOBE NEWSWIRE) — Janover Inc. (Nasdaq: JNVR) (“Janover” or the “Company”), an AI-enabled platform for commercial real estate transactions, today provided a business update, and announced its financial results for the first quarter ended March 31, 2024. Q1 2024 Key Financials 17% sequential increase in revenue for Q1 2024 compared to Q4 2023; 16% sequential increase in Small Business Administration (SBA) revenue for Q1 2024 compared to Q4 2023; Revenue per transaction increased 10% year-over-year for the first quarter ended March 31, 2024; 18% of the total revenue consisted of recurring subscription revenue in Q1 2024; $3.9...

YY Group Reports Full-Year 2023 Financial Results

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Revenue totaled $31.8 million, a 59% increase year-over-year Gross Profit was $3.7 million, a 42% increase year-over-year SINGAPORE, May 14, 2024 (GLOBE NEWSWIRE) — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group”, “YYGH”, or the “Company”), a data and technology-driven company that specializes in creating enterprise intelligent labor matching services and smart cleaning solutions, today announced its financial results for the full year ended December 31, 2023. “We are pleased to report growing revenues and increased gross profits for 2023, up 59% and 42% year-over-year, respectively,” said Mike Fu, Founder and Chief Executive Officer of YY Group. “With our recent IPO on the Nasdaq and expansion into new countries, we continue to successfully execute our strategic plan, to grow the Company and create value for our shareholders.” Full...

Genco Shipping & Trading Highlights Strong Results and 19th Consecutive Quarterly Dividend in Letter to Shareholders

Written by Customer Service on May 14, 2024. Posted in Dividend Reports And Estimates.

Successfully Executing on its Comprehensive Value Strategy Reminds Shareholders to Vote “FOR” Genco’s Nominees on the WHITE Proxy Card NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE: GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today mailed a letter to shareholders in connection with the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”), scheduled to be held on May 23, 2024. Shareholders of record as of March 28, 2024 will be entitled to vote at the meeting. The letter and information about how to vote at the meeting is available at www.VoteForGenco.com. The full text of the letter follows: Dear Genco shareholders, The Annual Meeting is approaching quickly, and we need your vote “FOR”...

Interim Management Statement covering Q3 2023/24

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Interim Management Statement covering Q3 2023/24 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the third quarter (1 January 2024– 31 March 2024) of the financial year 2023/24. Q3 highlights In Q1 through Q3 of the financial year 2023/24, the revenue amounted to DKK 29,3 million (Q1 to Q3 2022/23: DKK 20,7 million) or an increase of 41,6% (DKK 8,6 million). EBITDA in same period amounted to DKK 2,0 million (Q1 to Q3 2022/23: DKK 0,8 million) or an increase of DKK 1,2 million. The Company maintains a healthy and diverse order backlog of DKK 47,3 million, ranging across several different missions and customers in both institutional and commercial space. Execution of a number of parallel projects provides a positive operational outlook and improved robustness against external...

Bitcoin Depot Reports First Quarter 2024 Financial Results

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Strengthens Footprint with Over 2,000 New Retail Locations Signed in the First Quarter of 2024 Committed to Acquire Approximately 3,200 Additional Kiosks Year-to-Date to Support Expansion Strategy Remains on Track to Deploy 8,000 Kiosks by the End of 2024 ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the first quarter ended March 31, 2024. Bitcoin Depot will host a conference call and webcast at 10:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “Bitcoin Depot’s momentum continued in the first quarter as we fortified our industry-leading market share, expanded our footprint to new geographies, and purchased thousands...

Eviden announces JARVICE AI Platform Software as the latest addition to its growing AI computing portfolio

Written by Customer Service on May 14, 2024. Posted in Public Companies.

Press Release Eviden announces JARVICE AI Platform Software as the latest addition to its growing AI computing portfolio Paris, France and Hamburg, Germany – May 14, 2024 – Eviden, the Atos Group business leading in advanced computing, today announces JARVICE™ AI, a new software solution that complements its full BullSequana AI product and services line. JARVICE AI simplifies the work of data scientists and AI infrastructure administrators by providing a ‘single and secure pane of glass’ orchestration access to geographically dispersed GPU clusters or cloud providers. JARVICE AI is a comprehensive extension of Eviden’s existing JARVICE™ XE enterprise HPC platform. With new capabilities, this platform is designed for AI and can orchestrate one-click MLOps frameworks on advanced AI infrastructures, whether on-premises,...

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

Written by Customer Service on May 14, 2024. Posted in Public Companies.

ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference. A.G.P. 2024 Virtual Healthcare ConferenceFormat: Fireside Chat Presentation Date: Tuesday, May 21, 2024Presentation Time: 7:30 AM ETWebcast: Click here About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed...

Rani Therapeutics to Participate in May Investor Conferences

Written by Customer Service on May 14, 2024. Posted in Public Companies.

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include: H.C. Wainwright 2nd Annual BioConnect Investor ConferenceLocation: The Nasdaq Headquarters, New York CityDate: Monday, May 20th at 2:30pm E.TFormat: Fireside Chat and 1×1 Investor Meetings Presenter: Chief Executive Officer, Talat Imran UBS Spring Biotech ConferenceLocation: UBS, New York City Date: Tuesday, May 21st, 2024Format: 1×1 Investor Meetings Interested parties can register for and access the live webcast for the H.C. Wainright Conference by visiting the “Events”...

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Written by Customer Service on May 14, 2024. Posted in Public Companies.

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024. Fireside Chat detailsDate: Monday, May 20Time: 11:30 AM ETWebcast Link: https://journey.ct.events/view/ Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s...

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

Written by Customer Service on May 14, 2024. Posted in Public Companies.

ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for bempedoic acid, which is contained in NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. The certificate extends the term of U.S. Patent No. 7,335,799 by five years through December 3, 2030. The PTE certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984. This PTE will be listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration (FDA). INDICATION NEXLIZET and NEXLETOL are indicated: The bempedoic acid component of NEXLIZET...

Day: May 14, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice